Cancer treatment reviews · 2015
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio D, Muzii L, Tombolini V, Benedetti Panici P
Аннотация
For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.
Предметные рубрики MeSH
Antineoplastic AgentsCarcinomaClinical Trials, Phase II as TopicDrug Resistance, NeoplasmFemaleHumansMolecular Targeted TherapyMulticenter Studies as TopicNeoplasm ProteinsOrganoplatinum CompoundsOvarian NeoplasmsPeritoneal NeoplasmsProtein Kinase InhibitorsRandomized Controlled Trials as TopicRecurrenceTreatment Outcome